膳食中ω-6/ω-3多不饱和脂肪酸比例对非酒精性脂肪肝病的影响进展研究
Progress in the Study of the Effect of Dietary ω-6/ω-3 Polyunsaturated Fatty Acid Ratio on Non-Alcoholic Fatty Liver Disease
摘要: 非酒精性脂肪肝病(NAFLD)是指一种以肝脏脂肪过度堆积(肝细胞脂肪变性>5%)为核心特征的慢性代谢性疾病，其发病与酒精摄入无关，而与代谢综合征、胰岛素抵抗、肥胖、高血糖、高血脂及遗传因素密切相关。而ω-6和ω-3是人体必需的两种多不饱和脂肪酸，人类及其他哺乳动物无法自行合成，必须通过食物摄入来补充。近年来，膳食中多不饱和脂肪酸ω-6/ω-3比例的失衡被认为和NAFLD的发生相关。因此，主要综述了ω-6/ω-3 PUFAs比例对NAFLD的影响机制，并给出改善膳食结构、调和食用油等方法调整膳食中不饱和脂肪酸的比例，为疾病防治和公众健康饮食提供理论依据。
Abstract: Non-alcoholic fatty liver disease (NAFLD) refers to a chronic metabolic disease characterized by excessive accumulation of fat in the liver (hepatocyte steatosis >5%), which is unrelated to alcohol intake but closely associated with metabolic syndrome, insulin resistance, obesity, hyperglycemia, hyperlipidemia, and genetic factors. Omega-6 and omega-3 are two essential polyunsaturated fatty acids that humans and other mammals cannot synthesize on their own and must obtain through dietary intake. An imbalance in the dietary ratio of polyunsaturated fatty acids omega-6/omega-3 can trigger a series of metabolic syndromes, which is considered to be related to the occurrence of NAFLD. Therefore, this review primarily discusses the impact mechanism of the omega-6/omega-3 PUFAs ratio on the onset of NAFLD and provides methods to adjust the ratio of unsaturated fatty acids in the diet, such as improving dietary structure and balancing edible oils, to offer theoretical support for disease prevention and treatment as well as public healthy eating habits.
文章引用：冯靳一, 李欣璐, 尹靓瑶, 谢锁蕊, 黄梓馨, 陈雅静, 刘虹. 膳食中ω-6/ω-3多不饱和脂肪酸比例对非酒精性脂肪肝病的影响进展研究[J]. 生物医学, 2025, 15(4): 826-838. https://doi.org/10.12677/hjbm.2025.154088

参考文献

[1] 陈俊杰, 陈雅璐, 李春夏, 等. 中医药防治非酒精性脂肪性肝病研究进展[J]. 亚太传统医药, 2025, 21(4): 232-237.
[2] 范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版) [J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[3] 孔嘉宁, 张彬彬, 施军平.《代谢相关(非酒精性)肪性肝病防治指南(2024年版)》解读[J]. 临床肝胆病杂志, 2024, 40(9): 1767-1770.
[4] 杨敏, 魏冰, 孟橘, 等. ω-3多不饱和脂肪酸的来源及生理功能研究进展[J]. 中国油脂, 2019, 44(10): 110-115.
[5] Zhou, Z., Zhang, J., You, L., Wang, T., Wang, K., Wang, L., et al. (2022) Application of Herbs and Active Ingredients Ameliorate Non-Alcoholic Fatty Liver Disease under the Guidance of Traditional Chinese Medicine. Frontiers in Endocrinology, 13, Article ID:1000727. [Google Scholar] [CrossRef] [PubMed]
[6] Samuel, V.T. and Shulman, G.I. (2018) Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metabolism, 27, 22-41. [Google Scholar] [CrossRef] [PubMed]
[7] Fabbrini, E., Sullivan, S. and Klein, S. (2010) Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications. Hepatology, 51, 679-689. [Google Scholar] [CrossRef] [PubMed]
[8] Tilg, H. and Moschen, A.R. (2010) Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis. Hepatology, 52, 1836-1846. [Google Scholar] [CrossRef] [PubMed]
[9] Boursier, J. and Diehl, A.M. (2015) Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease. PLOS Pathogens, 11, e1004559. [Google Scholar] [CrossRef] [PubMed]
[10] Day, C. and Anstee, Q. (2015) The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and Tm6SF2. Seminars in Liver Disease, 35, 270-290. [Google Scholar] [CrossRef] [PubMed]
[11] Cui, D., Wang, Z., Dang, Q., Wang, J., Qin, J., Song, J., et al. (2023) Spliceosome Component Usp39 Contributes to Hepatic Lipid Homeostasis through the Regulation of Autophagy. Nature Communications, 14, Article No. 7032. [Google Scholar] [CrossRef] [PubMed]
[12] Lin, Y., Yang, M., Huang, L., Yang, F., Fan, J., Qiang, Y., et al. (2023) A Bacteria-Derived Tetramerized Protein Ameliorates Nonalcoholic Steatohepatitis in Mice via Binding and Relocating Acetyl-Coa Carboxylase. Cell Reports, 42, Article 113453. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, W., Tan, J., Liu, X., Guo, W., Li, M., Liu, X., et al. (2023) Cytoplasmic Endonuclease G Promotes Nonalcoholic Fatty Liver Disease via MTORC2-AKT-ACLY and Endoplasmic Reticulum Stress. Nature Communications, 14, Article No. 6201. [Google Scholar] [CrossRef] [PubMed]
[14] Bai, L., Qu, W., Cheng, X., Yang, H., Huang, Y., Wang, Z., et al. (2024) Multispecies Transcriptomics Identifies SIKE as a MAPK Repressor That Prevents NASH Progression. Science Translational Medicine, 16, eade7347. [Google Scholar] [CrossRef] [PubMed]
[15] 鲍建民. 多不饱和脂肪酸的生理功能及安全性[J]. 中国食物与营养, 2006(1): 45-46.
[16] 王雪青, 苗惠, 胡萍. 膳食中多不饱和脂肪酸营养与生理功能的研究进展[J]. 食品科学, 2004, 25(11): 337-339.
[17] Mariamenatu, A.H. and Abdu, E.M. (2021) Overconsumption of Omega-6 Polyunsaturated Fatty Acids (PUFAS) versus Deficiency of Omega-3 PUFAs in Modern-Day Diets: The Disturbing Factor for Their “Balanced Antagonistic Metabolic Functions” in the Human Body. Journal of Lipids, 2021, Article ID: 8848161. [Google Scholar] [CrossRef] [PubMed]
[18] 官玲亮. 红花(Carthamus tinctorius L.)不同组织多不饱和脂肪酸积累模式及调控机制[D]: [博士学位论文]. 雅安: 四川农业大学, 2011
[19] Pewan, S.B., Otto, J.R., Huerlimann, R., Budd, A.M., Mwangi, F.W., Edmunds, R.C., et al. (2020) Genetics of Omega-3 Long-Chain Polyunsaturated Fatty Acid Metabolism and Meat Eating Quality in Tattykeel Australian White Lambs. Genes, 11, Article 587. [Google Scholar] [CrossRef] [PubMed]
[20] Katalin, N. and Ioana-Daria, T. (2017) Importance of Fatty Acids in Physiopathology of Human Body. IntechOpen.
[21] 徐华兴, 韦晓玲. 多不饱和脂肪酸代谢产物在口腔疾病中的作用及应用研究进展[J]. 口腔医学, 2024, 44(7): 545-550.
[22] 陈璎, 李茹, 吴海冲. n-3多不饱和脂肪酸改善宠物皮肤炎症的应用与机理研究进展[J/OL]. 经济动物学报, 1-7.
http://119.29.172.80:8085/kcms/detail/22.1258.S.20240919.1757.002.html, 2024-11-19.
[23] Arshad, R., Wan, J., Ai, T., Yin, C., Qin, Y., Qin, R., et al. (2025) A Targeted Reformulation of Safflower Oil: Enhancing Anti-Inflammatory Potential and Market Competitiveness through Ω3 Enrichment. Food Research International, 203, Article 115793. [Google Scholar] [CrossRef] [PubMed]
[24] 王琼. 不饱和脂肪酸对肥胖患者脂代谢和脂肪酸分布的影响[D]: [博士学位论文]. 无锡: 江南大学, 2023.
[25] 刘睿杰, 王莉梅, 常明, 等. ω-6/ω-3多不饱和脂肪酸比例对HepG2细胞脂代谢的影响[J]. 现代食品科技, 2017, 33(1): 1-7.
[26] 吕玉珊, 罗玮, 宋佳, 等. ω-6/ω-3多不饱和脂肪酸对3T3-L1脂肪细胞脂联素及PPARγ表达的调节作用[J]. 营养学报, 2016, 38(2): 152-156.
[27] 柳先丽, 舒晓亮, 徐涵, 等. ω-3多不饱和脂肪酸对疾病炎症反应影响的Meta分析[J]. 同济大学学报(医学版), 2014, 35(6): 17-22+58.
[28] 倪犇. ω-3多不饱和脂肪酸对炎症肠道性疾病的改善作用[D]: [硕士学位论文]. 北京: 中国农业科学院, 2023.
[29] 肥胖症诊疗指南(2024年版) [J]. 中国循环杂志, 2025, 40(1): 6-30.
[30] 中国肥胖问题工作组数据汇总分析协作组. 我国成人体重指数和腰围对相关疾病危险因素异常的预测价值: 适宜体重指数和腰围切点的研究[J]. 中华流行病学杂志, 2002(1): 10-15.
[31] 林荫. 体重指数对2型糖尿病常见并发症与代谢指标的影响及中医证型研究[D]: [硕士学位论文]. 沈阳: 辽宁中医药大学, 2024.
[32] 蔡芳玲. 口服葡萄糖耐量试验: 糖尿病诊断的金标准[J]. 糖尿病之友, 2025(1): 38-39.
[33] 中国2型糖尿病防治指南(2017年版) [J]. 中国实用内科杂志, 2018, 38(4): 292-344.
[34] 王克安, 李天麟, 向红丁, 等. 中国糖尿病流行特点研究糖尿病和糖耐量低减患病率调查[J]. 中华流行病学杂志, 1998(5): 27-30.
[35] 韦娜. 膳食中不同n-6/n-3多不饱和脂肪酸构成对乳腺癌发生发展的影响及分子机制研究[D]: [博士学位论文]. 重庆: 第三军医大学, 2006.
[36] Weiser, M.J., Butt, C.M. and Mohajeri, M. (2016) Docosahexaenoic Acid and Cognition Throughout the Lifespan. Nutrients, 8, Article 99. [Google Scholar] [CrossRef] [PubMed]
[37] 胡晓军, 李群, 梁霞. 脂肪酸配比合理的调和油的研究[J]. 山西农业科学, 2006, 34(2): 79-81.
[38] 曹文婷. 膳食n-6/n-3多不饱和脂肪酸配比对大鼠溃疡性结肠炎影响及其机制研究[D]: [硕士学位论文]. 太原: 山西医科大学, 2013.
[39] 张晓霞, 米树华, 李斌, 等. 植物油降低心脏ω-6/ω-3多不饱和脂肪酸比值并改善心肌缺血再灌注的研究[J]. 心肺血管病杂志, 2013, 32(6): 773-776.
[40] 伍金华, 周克元. 调节食物中ω-6和ω-3脂肪酸合适比例研究的进展[J]. 国外医学卫生学分册, 2006, 33(2): 70-73.
[41] 何雁南, 赵锋, 刘英华. 脂代谢平衡防治肿瘤发生、发展的研究进展[J]. 肿瘤代谢与营养电子杂志, 2024, 11(4): 473-479.
[42] 燕志, 朱江煜, 魏继燕, 等. n-3/n-6多不饱和脂肪酸的生理功能与膳食平衡研究[J]. 江苏调味副食品, 2022(3): 1-3.
[43] Zec, M.M., Krga, I., Takić, M., Debeljak-Martačić, J., Korićanac, G., Ranković, S., et al. (2020) Walnut Consumption Induces Tissue-Specific Omega-6/Omega-3 Decrease in High-Fructose-Fed Wistar Rats. ACS Omega, 5, 28136-28145. [Google Scholar] [CrossRef] [PubMed]
[44] Ting, L., Omar, M.-G., Allysa, A., et al. (2016) Consumption of Walnuts in Combination with Other Whole Foods Produces Physiologic, Metabolic, and Gene Expression Changes in Obese C57BL/6J High-Fat-Fed Male Mice. The Journal of Nutrition, 146, 1641-1650. [Google Scholar] [CrossRef] [PubMed]
[45] 段叶辉, 李凤娜, 李丽立, 等. n-6/n-3多不饱和脂肪酸比例对机体生理功能的调节[J]. 天然产物研究与开发, 2014, 26(4): 626-631+479.
[46] Harrison, S.A., Taub, R., Neff, G.W., Lucas, K.J., Labriola, D., Moussa, S.E., et al. (2023) Resmetirom for Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial. Nature Medicine, 29, 2919-2928. [Google Scholar] [CrossRef] [PubMed]
[47] Sookoian, S. and Pirola, C.J. (2024) Resmetirom for Treatment of MASH. Cell, 187, 2897-2897.E1. [Google Scholar] [CrossRef] [PubMed]
[48] Ding, J., Liu, H., Zhang, X., Zhao, N., Peng, Y., Shi, J., et al. (2024) Integrative Multiomic Analysis Identifies Distinct Molecular Subtypes of NAFLD in a Chinese Population. Science Translational Medicine, 16, eadh9940. [Google Scholar] [CrossRef] [PubMed]

为你推荐